Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo

Hypertension

Volumn 61, Issue 2, 2013, Pages 361-367

  Messaoudi, Smail ^a   Gravez, Basile ^a   Tarjus, Antoine ^a   Pelloux, Véronique ^a   Ouvrard Pascaud, Antoine ^b   Delcayre, Claude ^c   Samuel, Janelise ^c   Launay, Jean Marie ^c   Sierra Ramos, Catalina ^d   De La Rosa, Diego Alvarez ^d   Clément, Karine ^a   Farman, Nicolette ^a   Jaisser, Fréderic ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c APHP   (France)

^d UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

aldosterone; connective tissue growth factor; gene microarray; mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTERONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; TRANSCRIPTOME;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; EX VIVO STUDY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; HEART FAILURE; HEART MUSCLE CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR BINDING;

ALDOSTERONE; ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; MICE; MICE, TRANSGENIC; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCYTES, CARDIAC; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TRANSCRIPTOME;

EID: 84873055223     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.198986     Document Type: Article

References (34)

1. Konishi A, Tazawa C, Miki Y, Darnel AD, Suzuki T, Ohta Y, Suzuki T, Tabayashi K, Sasano H. The possible roles of mineralocorticoid receptor and 11?-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol. 2003;85:439-442. (Pubitemid 37011119)
2. Milik E, Szczepa?ska-Sadowska E, Ma?li?ski W, Cudnoch-Jedrzejewska A. Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats. J Physiol Pharmacol. 2007;58:745-755.
3. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007;292:R946-R954. (Pubitemid 46207752)
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
6. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
7. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427. (Pubitemid 40204425)
8. Wang D, Liu YH, Yang XP, Rhaleb NE, Xu J, Peterson E, Rudolph AE, Carretero OA. Role of a selective aldosterone blocker in mice with chronic heart failure. J Card Fail. 2004;10:67-73. (Pubitemid 38885720)
9. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008;52:1060-1067.
10. Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J Suppl. 2011;13:B4-B9.
11. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G, Bauersachs J. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400-408.
12. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. (Pubitemid 40847778)
13. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuillez C, Jaisser F, Richard V. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol. 2011;300:H2035-H2043.
14. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275. (Pubitemid 17095145)
15. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585. (Pubitemid 18263202)
16. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11?-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
17. Gomez AM, Rueda A, Sainte-Marie Y, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009;119:2179-2187.
18. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci. 2007;113:267-278. (Pubitemid 47372685)
19. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, Perret C, Lopez Andres N, Rossignol P, Zannad F, Farman N, Jaisser F. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension. 2012;59:966-972.
20. Vallon V, Wyatt AW, Klingel K, et al. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med. 2006;84:396-404. (Pubitemid 43673614)
21. Wong S, Tan K, Carey KT, Fukushima A, Tiganis T, Cole TJ. Glucocorticoids stimulate hepatic and renal catecholamine inactivation by direct rapid induction of the dopamine sulfotransferase Sult1d1. Endocrinology. 2010;151:185-194.
22. Laszlo R, Bentz K, Konior A, Eick C, Schreiner B, Kettering K, Schreieck J. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:347-356.
23. Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T, Schirdewan A, Reuter H, Mueller-Ehmsen J, Zobel C. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol. Epub ahead of print July 14, 2011.
24. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010;33:572-577.
25. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286-290.
26. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280:F181-F192.
27. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761. (Pubitemid 46648612)
28. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171-2179.
29. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf). 2009;195:321-338.
30. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol. 2011;31:1871-1880.
31. Gauer S, Segitz V, Goppelt-Struebe M. Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol Dial Transplant. 2007;22:3154-3159. (Pubitemid 350202564)
32. Lee YS, Kim JA, Kim KL, Jang HS, Kim JM, Lee JY, Shin IS, Lee JS, Suh W, Choi JH, Jeon ES, Byun J, Kim DK. Aldosterone upregulates connective tissue growth factor gene expression via p38 MAPK pathway and mineralocorticoid receptor in ventricular myocytes. J Korean Med Sci. 2004;19:805-811. (Pubitemid 40104871)
33. Brigstock DR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal. 2010;4:1-4.
34. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901. (Pubitemid 23002899)